| | |
EGFR (ErbB-1)
|
HER2-neu (ErbB-2)
| |
|---|
|
Histopathological subtype (N = 52)
| |
IHC (N = 31)
|
FISH (N = 27)
|
TKD Mutation (N = 68)
|
IHC (N = 31)
|
FISH (N = 6) amplification
|
TKD Mutation (N = 68)
|
|---|
| | |
0
|
1+
|
2/3+
|
< 2
|
P
| |
0
|
1+
|
2/3+
| | |
|---|
|
Adenocarcinoma:
| | | | | | | | | | | | |
|
Serous
|
27
|
7
|
4
|
8
|
17
|
3
|
34
|
11
|
4
|
4
|
2
|
34
|
|
Mucinous
|
4
|
1
|
1
|
1
|
3
|
0
|
6
|
3
|
0
|
0
|
0
|
6
|
|
Endometroid
|
21
|
3
|
2
|
4
|
7
|
1
|
28
|
5
|
2
|
2
|
1
|
28
|
- Fifty-two ovarian tumours were analyzed by immunohistochemistry, FISH and mutation status for EGFR (ErBb-1) and HER2-neu (ErBb-2). The IHC scores and definition of gene amplification are specified in the methods section. For EGFR no amplification was found. For HER2-neu the gene copy number was only examined in the 6 cancers with 2/3+ IHC.
- N = number of cases, P = "high polysomy", 0 = absent, TKD = tyrosine kinase domain.
